The agency’s reasoning for the decision is grounded in lab data that found the antibody cocktail is not effective against P.1 (Brazilian) or B.1.351 (South African) variants. Those variants comprise more than 10% of COVID-19 infections in the eight states mentioned above.
Earlier this year, FDA withdrew the EUA for Lilly’s bamlanivimab but continued to authorize its use when paired with etesevimab. The reasoning for doing so was that bamlanivimab alone was ineffective against some SARS-CoV-2 variants.
Filed Under: Infectious Disease